Papillon Study News Today

Standard-of-Care Approaches in EGFR-Mutant NSCLC

December 6, 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study

December 1, 2023

Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Marka Socinski First Line Treatment Mutated Advanced Primary Results From Randomized Phase Papillon Study

Source: onclive.com

Navigation

Papillon Study News Today

Standard-of-Care Approaches in EGFR-Mutant NSCLC

Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study

Explore More Categories

Navigation

Papillon Study News Today

Standard-of-Care Approaches in EGFR-Mutant NSCLC

Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion&#x2013;Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study

Explore More Categories

Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study